association of gstm1 null allele with prostate cancer risk evidence from 36 case-control studies协会gstm1基因无效等位基因与前列腺癌风险来自36个病例对照研究的证据.pdf

Association of GSTM1 Null Allele with Prostate Cancer Risk: Evidence from 36 Case-Control Studies 1. 1 . 2. 1 3 4 1 1 Bingbing Wei , Zhuoqun Xu * , You Zhou , Jun Ruan , Huan Cheng , Bo Xi , Ming Zhu , Ke Jin , 1 1 1 1 1 1 1 Deqi Zhou , Qiang Hu , Qiang Wang , Zhirong Wang , Zhiqiang Yan , Feng Xuan , Xing Huang , Jian Zhang1, Hongyi Zhou1 1 Department of Urology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, China, 2 Faculty of Medicine, University of Helsinki, Finland, 3 Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 4 Department of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, China Abstract Background: Glutathione S-transferase M1 (GSTM1) is thought to be involved in detoxifying several carcinogens and may play a vital role in tumorigenesis. Numerous studies have evaluated the association between GSTM1 null/present polymorphism and risk of prostate cancer (PCa). However, the results remain inconsistent. To derive a more precise estimation, we performed a meta-analysis. Methodology/Principal Findings: A comprehensive search was conducted to identify all eligible case-control studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. The overall association was significant (OR = 1.28, 95% CI: 1.11–1.48, P = 0.001). Moreover, subgroup analyses showed GSTM1 null genotype significantly associated with PCa risk among